In vitro and in silico studies reveal antidiabetic property of arylbenzofurans from the root bark of Morus mesozygia Stapf

Katherine Olabanjo Olufolabo,Kai Lüersen,Samuel Ayoolu Oguntimehin,Vaderament-A. Nchiozem-Ngnitedem,Emmanuel Ayodeji Agbebi,Kolade Olatubosun Faloye,Divinah Kwamboka Nyamboki,Gerald Rimbach,Josphat Clement Matasyoh,Bernd Schmidt,Jones Olanrewaju Moody
DOI: https://doi.org/10.3389/fphar.2024.1338333
IF: 5.6
2024-02-24
Frontiers in Pharmacology
Abstract:Diabetes remains an important disease worldwide with about 500 million patients globally. In tropical Africa, Morus mesozygia is traditionally used in the treatment of diabetes. Biological and phytochemical investigation of the root bark extracts of the plant led to the isolation of a new prenylated arylbenzofuran named 7-(3-hydroxy-3-methylbutyl)moracin M ( 1 ) and two congeners, moracins P ( 2 ) and M ( 3 ). When compared to acarbose (IC 50 = 486 μM), all the isolated compounds are better inhibitors of α-glucosidase with in vitro IC 50 values of 16.9, 16.6, and 40.9 μM, respectively. However, they were not active against α-amylase. The compounds also demonstrated moderate inhibition of dipeptidyl peptidase-4 (DPP4). Based on in silico docking studies, all isolates ( 1 , 2 , and 3 ) exhibit binding affinities of −8.7, −9.5, and −8.5 kcal/mol, respectively against α-glucosidase enzyme (PDB: 3AJ7). They are stabilized within the α-glucosidase active site through hydrogen bonds, pi interactions, and hydrophobic interactions. This study provides scientific support for the traditional use of Morus mesozygia in the treatment of diabetes as well as adding to the repository of α-glucosidase inhibitory agents.
pharmacology & pharmacy
What problem does this paper attempt to address?